FMP
Savara Inc.
SVRA
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
5.16 USD
0.12 (2.33%)
About
ceo
Mr. Matthew Pauls J.D., M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.savarapharma.com
exchange
NASDAQ
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CIK
0001160308
ISIN
US8051111016
CUSIP
805111101
Address
Building III
Phone
512 614 1848
Country
US
Employee
37
IPO Date
Apr 28, 2017
Summary
CIK
0001160308
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
805111101
ISIN
US8051111016
Country
US
Price
5.16
Beta
0.7
Volume Avg.
814.68k
Market Cap
712.84M
Shares
-
52-Week
1.75-5.7
DCF
-0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-15.64
P/B
-
Website
https://www.savarapharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SVRA News
It looks like there's no news available.
